# This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

> **NCT03713619** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 544 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** secukinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03713619
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-31
- **Primary completion:** 2021-10-01
- **Final completion:** 2022-07-26
- **Target enrollment:** 544 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03713619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03713619, "This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03713619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*